
Champions Oncology CSBR
$ 5.78
-1.45%
Quarterly report 2025-Q4
added 03-12-2026
Champions Oncology Cost of Revenue 2011-2026 | CSBR
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Champions Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.4 M | 29.4 M | 29.5 M | 23.6 M | 21.4 M | 17 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 29.5 M | 17 M | 24.9 M |
Quarterly Cost of Revenue Champions Oncology
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.83 M | 8 M | - | 6.62 M | 7.43 M | 7.07 M | - | 6.62 M | 7.68 M | - | 6.41 M | 7.44 M | 7.05 M | - | 4.62 M | 5.61 M | 11 M | - | 4.32 M | 5.64 M | 5.64 M | 5.34 M | 3.43 M | 3.88 M | 3.88 M | 3.75 M | 2.47 M | 3.45 M | 3.45 M | 3.08 M | - | 2.65 M | 2.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11 M | 2.47 M | 5.48 M |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
32.2 M | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
364 M | $ 21.87 | 2.15 % | $ 1.02 B | ||
|
I-Mab
IMAB
|
27.2 M | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M | ||
|
Aptorum Group Limited
APM
|
421 K | $ 0.9 | - | $ 6.62 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
81.8 M | $ 22.28 | 1.46 % | $ 3.69 B | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
145 M | - | 1.93 % | $ 17.4 M | ||
|
Ampio Pharmaceuticals
AMPE
|
369 K | - | -11.43 % | $ 502 K | ||
|
Aeterna Zentaris
AEZS
|
90 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
40 K | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
2.91 B | $ 105.26 | -0.19 % | $ 27.2 B | ||
|
Aquestive Therapeutics
AQST
|
18.6 M | $ 4.1 | 0.37 % | $ 438 M | ||
|
Arcutis Biotherapeutics
ARQT
|
36.7 M | $ 23.98 | 3.07 % | $ 3.05 B | ||
|
Ayala Pharmaceuticals
AYLA
|
602 K | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
96.4 M | $ 1.47 | 1.74 % | $ 391 M | ||
|
AstraZeneca PLC
AZN
|
12.4 B | - | - | $ 96.9 B | ||
|
BioDelivery Sciences International
BDSI
|
23.4 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
70.7 M | - | 0.49 % | $ 251 B | ||
|
CureVac N.V.
CVAC
|
238 M | - | - | $ 867 M | ||
|
bluebird bio
BLUE
|
33.5 M | - | - | $ 546 M | ||
|
ContraFect Corporation
CFRX
|
1.6 M | - | -5.16 % | $ 5.39 M | ||
|
Cardiff Oncology
CRDF
|
597 K | $ 1.72 | - | $ 115 M | ||
|
BioXcel Therapeutics
BTAI
|
164 K | $ 1.1 | 3.76 % | $ 13.4 M | ||
|
CASI Pharmaceuticals
CASI
|
12.6 M | - | - | $ 35.4 M |